Search 

ALIAD is the venture capital subsidiary of the Air Liquide Group (L'Air Liquide S.A.), one of the largest multinational providers of industrial and medical gases and related activities, headquartered in Paris, France. The healthcare division of the Air Liquide Group has been playing a significant role in healthcare with over €2 billion in revenue. 
ALIAD aims to promote the Group’s growth and access to innovations through taking minority stakes in innovative technology start-ups outside the Group. ALIAD can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. ALIAD is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Brace Pharmaceuticals is based in Rockville, MD, and is a strategic investment company formed by Brazil-based pharma company EMS S/A. Brace investment structure varies depending on a company’s development stage; for early-stage opportunities Brace typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities Brace is more likely to form strategic partnerships that involve rights to an asset. Brace is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

Brace Pharmaceuticals invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities. Drug-device combinations will also be considered, but Brace does not invest in diagnostics. The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

Debra Miller co-founded CureDuchenne in 2003 with her husband, Paul, after their only son was diagnosed with Duchenne. Miller relies on her extensive background in sales and marketing to lead CureDuchenne. 

Her role includes overseeing all operations, research and financial resources as well as serving as the primary liaison to the Board of Directors. She is the decision maker, leader and manager in carrying out the mission of the organization. She also works closely with the Scientific Board of Advisors in designing and implementing the medical research strategic plan.

Miller is a member of the Department of Defense Duchenne Research review board and also a member of the TREAT-NMD international review board, TACT.  Miller has led CureDuchenne’s successful venture philanthropy programs and is the architect of CureDuchenne Ventures LLC, a new, for profit entity created to attract significant research funding to Duchenne research.

Prior to CureDuchenne, Miller had a career in publishing with positions at IDG Communications, Cahners Publishing, Ziff-Davis Publishing and Scholastic Publishing. She also worked in management at PC Magazine and was an independent stock trader.

Miller earned a Bachelor of Arts in Communication Studies from the University of California – Los Angeles. 

Lilly Asia Ventures is the venture capital arm of Eli Lilly that focuses on investments in the life sciences in Asia, particularly China. The firm was established in 2008 and is based in Shanghai, China. The firm is stage agnostic; investing in early, growth, and up to pre-IPO opportunities. The firm’s investment size is USD 5-20 million per company. The firm primarily invests in companies in China, but is open to companies across Asia-Pacific as long as there is some sort of China angle. The firm is actively seeking new investment opportunities.

Lilly Asia Ventures primarily focuses on therapeutics but is also interested in medical devices, diagnostics, animal health, and biotech other. The firm is most interested in products that will have a significant impact on medical care in China. For therapeutics, the firm seeks best-in-class or first-in-class products. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA. Historically, the firm invests in therapeutics for oncology, inflammatory diseases, and metabolic disorders.

Mayo Clinic Ventures serves to commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic. The office has licensed hundreds of technologies in the fields of medical devices, diagnostics, therapeutics, and healthcare IT, and has focused efforts in technology-based ventures and start-ups.  Mayo Clinic Ventures also has a $20M venture capital fund which is used to spin out companies that are developing products based on Mayo Clinic research.

Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.

MP Healthcare Ventures is the corporate venture arm of Mitsubishi Tanabe Pharma founded in 2006 and based in Boston Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.